SCHEMBL6797552

SCHEMBL6797552

CCOC(=O)c1cc2c(C)c(OCc3ccccc3)ccc2n1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
SRD5A2 P31213 2/20 0.47
SRD5A1 P18405 1/20 0.47
MAPT P10636 3/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
ALOX5 P09917 1/20 0.45
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAOA P21397 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4997665 0.87 SRD5A2 (0.47) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL7884800 0.80 KMT2A (0.43) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL27252499 0.78 KMT2A (0.42) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL8687408 0.78 SRD5A2 (0.76) GAASRD5A2SRD5A1KMT2AMEN1
SCHEMBL31412992 0.78 SRD5A2 (0.78) SMN1; SMN2HPGDSRD5A2SRD5A1MAOA
SCHEMBL7881965 0.78 SRD5A2 (0.47) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL7246268 0.78 ALDH1A1 (0.41) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL7879826 0.78 ALOX5 (0.42) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL19332328 0.77 SRD5A2 (0.49) KDM4ELMNAGAASMN1; SMN2ALDH1A1
SCHEMBL6798709 0.76 ALDH1A1 (0.46) KDM4ELMNAGAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 KDM4E 1068/4885LMNA 1165/4885GAA 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.